Yongqiang Tang

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

P. Rolan, E. Aycardi, G. O'neill, 2015, PloS one.

Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

B. Ravina, E. Aycardi, A. Verma, 2016, British journal of clinical pharmacology.

Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.

Yingmei Wang, P. Hogendoorn, Jiayan Liu, 2021, Annals of diagnostic pathology.

[Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis].

D. Cadavid, G. O'neill, Yongqiang Tang, 2010, Revista de neurologia.

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema

Moshe Y. Vardi, E. Aygören‐Pürsün, I. Martínez-Saguer, 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.

William H. Yang, Moshe Y. Vardi, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Poorly differentiated chordoma

Li Yang, Yingmei Wang, Hong Cheng, 2022, Human Pathology Reports.

[EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].

Moshe Y. Vardi, E. Morita, K. Eto, 2020, Arerugi = [Allergy].

Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation

A. Deykin, Yongqiang Tang, M. Matson, 2011, Current medical research and opinion.